• Gene deletion; HGNC; HGNC:9588; PTEN; Zygosity=Heterozygous (PubMed=22194965).
  
• Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22194965; PubMed=27533468).
  
• Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=22194965; PubMed=27533468).
  

PubMed=22194965; DOI=10.1371/journal.pone.0028973; PMCID=PMC3237573
Mohammad Atefi, Erika Maria von Euw, Narsis Attar, Charles Ng, Connie Chu, De-Liang Guo, Ramin Nazarian, Bartosz Chmielowski, John A. Glaspy, Begonya Comin-Anduix, Paul Salomon Mischel ...Show all 13 authors... , Roger S. Lo, Antoni Ribas; Show fewer authors
Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.
PLoS ONE 6:e28973.1-e28973.12(2011)

PubMed=27533468; DOI=10.1080/15384101.2016.1208862; PMCID=PMC5026796
Helene Malka-Mahieu, Isabelle Girault, Margot Rubington, Melissa Leriche, Caroline Welsch, Nyam Kamsu-Kom, Qian Zhao, Laurent Desaubry, Stephan Vagner, Caroline Robert;
Synergistic effects of eIF4A and MEK inhibitors on proliferation of NRAS-mutant melanoma cell lines.
Cell Cycle 15:2405-2409(2016)